thrombolysis in myocardial infarction


Also found in: Acronyms, Wikipedia.

thrombolysis in myocardial infarction

,

TIMI

A large series of studies on the use of thrombolytic drugs and percutaneous coronary intervention in patients with acute coronary syndromes. The studies are sponsored by the Thrombolysis in Myocardial Infarction Study Group (TIMI Study Group). Website: www.timi.org
References in periodicals archive ?
Performance of the thrombolysis in myocardial infarction risk index in the National Registry of Myocardial Infarction-3 and -4: a simple index that predicts mortality in ST-segment elevation myocardial infarction.
Validation of the Thrombolysis In Myocardial Infarction (TIMI) risk index for predicting early mortality in a population-based cohort of STEMI and non-STEMI patients.
In patients with acute STEMI, thrombolysis in myocardial infarction (TIMI) frame counts may show significant variability despite presence of grade 3 TIMI flow after successful reperfusion and lower TIMI frame counts after reperfusion are associated with more favorable prognosis (7).
In accordance with convention, patency in the infarct-related artery is graded by angiography according to the Thrombolysis in Myocardial Infarction (TIMI) criteria, in which TIMI 0 is no perfusion past the occlusion; TIMI 1 is penetration past the occlusion without perfusion; TIMI 2 is partial perfusion past the occlusion; and TIMI 3 is complete perfusion (63).
The study will be conducted by the Thrombolysis in Myocardial Infarction Study Group, a US-based investigative team at the forefront of clinical research into acute coronary syndromes.
Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy.
Director of the Thrombolysis in Myocardial Infarction (TIMI) research network at Harvard University in Boston, MA.
Results of the COMMIT/CCS-2 (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) and CLARITY - TIMI 28 (CLopidogrel as Adjunctive ReperfusIon TherapY - Thrombolysis In Myocardial Infarction Study 28) trials, which included a total of nearly 50,000 patients, were presented today in Orlando, Florida at the 54th Annual Scientific Session of the American College of Cardiology (ACC).
The study will be coordinated by the Thrombolysis In Myocardial Infarction (TIMI) Study Group.
The TIMI studies are conducted by the Thrombolysis in Myocardial Infarction (TIMI) group at the Brigham and Women's Hospital in Boston.